Stock listing

NASDAQ:VOR Vor Biopharma Inc. Stock

Home listing (NASDAQ) of Vor Biopharma Inc.

Follow Vor Biopharma Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VOR

$19.19 USD +1.36 (+7.6%)

Close on Nov 20, 2026

Past year +179.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$17.99 – $19.91 USDNov 20, 2026
Volume
1.55M sharesNov 20, 2026
Market cap
$1.18B USDAt the close on Nov 20, 2026 · price × 61.43M shares outstanding
52-week range
$6.69 – $26.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$19.18M USDMedian day 793,988 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Vor Biopharma Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VOR · Home$19.19 USD+1.36 (+7.6%)1,554,050$18.14$19.91$17.99$17.83Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VOR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$19.19+1.36+7.6%$18.14$19.91$17.991,554,050
$17.83-0.35-1.9%$17.85$18.53$17.78793,988
$18.18-0.79-4.2%$18.96$19.16$17.74826,250
$18.97-0.45-2.3%$19.01$20.29$18.86763,208
$19.42+0.10+0.5%$19.33$19.49$18.16738,717
$19.32-0.77-3.8%$19.61$19.88$18.99796,406
$20.09+0.53+2.7%$19.73$20.30$19.57407,723
$19.56-0.42-2.1%$19.75$20.23$19.26405,778
$19.98+0.10+0.5%$19.70$20.61$19.701,095,633
$19.88+1.22+6.5%$19.11$20.00$18.63550,771
$18.66-1.46-7.3%$20.08$20.08$18.33629,047
$20.12+0.26+1.3%$20.63$20.70$19.49415,417
$19.86+0.61+3.2%$19.45$20.63$18.93905,009
$19.25-0.43-2.2%$19.71$20.00$18.84624,085
$19.68-1.23-5.9%$19.91$20.47$19.37759,293
$20.91+0.26+1.3%$20.80$21.59$20.66965,843
$20.65+1.11+5.7%$19.50$20.81$19.381,011,532
$19.54+1.21+6.6%$18.36$19.56$18.02769,881
$18.33+0.07+0.4%$18.33$18.44$17.70470,337
$18.26-0.68-3.6%$18.67$18.81$17.95721,000
$18.940.000.0%$18.87$19.44$18.65722,400
$18.94-0.09-0.5%$19.18$19.79$18.79817,600
$19.03+0.99+5.5%$18.06$19.55$18.00796,000
$18.04+0.01+0.1%$18.37$18.72$17.73724,800
$18.03-1.31-6.8%$19.45$19.45$18.00733,100
$19.34+0.59+3.1%$18.85$20.25$18.78696,600
$18.75-0.31-1.6%$18.79$19.74$18.55926,900
$19.06-0.74-3.7%$19.50$19.95$18.98949,400
$19.80-0.10-0.5%$19.79$20.52$19.55867,400
$19.90+0.77+4.0%$18.99$20.27$18.851,102,400
$19.13+0.35+1.9%$18.64$19.88$18.081,406,600
$18.78+0.47+2.6%$18.09$18.90$17.86563,100
$18.31-0.27-1.5%$18.85$18.87$17.97472,800
$18.58-0.11-0.6%$18.63$19.18$18.07648,500
$18.69+0.63+3.5%$18.09$18.99$18.09773,300
$18.06-1.02-5.3%$18.97$19.30$18.00876,200
$19.08+0.75+4.1%$18.54$19.81$18.381,069,900
$18.33+0.02+0.1%$18.63$18.77$17.521,384,000
$18.31-0.21-1.1%$18.36$18.74$18.02930,100
$18.52+0.08+0.4%$18.62$18.71$17.95792,800
$18.44-0.93-4.8%$19.02$19.37$17.551,931,500
$19.37-2.63-12.0%$22.00$22.02$18.892,763,500
$22.00+0.11+0.5%$21.83$23.82$21.612,586,500
$21.89+0.49+2.3%$21.82$22.16$21.441,864,100
$21.40-0.49-2.2%$21.92$22.00$21.233,725,700
$21.89-0.06-0.3%$22.53$23.05$21.801,544,200
$21.95-0.37-1.7%$22.39$22.52$21.811,496,400
$22.32-0.76-3.3%$23.06$23.06$22.04729,800
$23.08+0.78+3.5%$22.39$23.56$22.27886,100
$22.30-0.04-0.2%$22.83$23.47$22.20800,400
$22.34-0.895-3.9%$22.96$23.09$22.09689,300
$23.24-1.865-7.4%$24.47$24.60$23.21823,200
$25.10+0.05+0.2%$24.75$26.00$24.10856,700
$25.05+0.81+3.3%$24.17$25.17$24.00421,800
$24.24-0.52-2.1%$24.80$24.94$23.88538,800
$24.76+2.12+9.4%$22.77$24.88$22.67824,900
$22.64+0.16+0.7%$22.32$22.88$22.05607,300
$22.48-0.17-0.8%$22.50$22.76$22.28847,700
$22.65-0.88-3.7%$23.20$23.29$22.38491,100
$23.53-0.14-0.6%$23.62$23.99$23.14622,100
$23.67-0.34-1.4%$23.68$24.09$23.39446,700
$24.01+1.30+5.7%$23.02$24.45$23.021,219,900
$22.71-0.65-2.8%$23.12$23.18$21.90500,000
$23.36+0.295+1.3%$23.58$23.86$23.07618,100
$23.07-0.515-2.2%$23.05$23.41$22.79649,600

Splits

1 split · NASDAQ:VOR · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:VOR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Vor Biopharma Inc. news

Vor Biopharma Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 107 in all · newest Nov 12, 2026 · oldest 2021
Decks
13 decks · latest Oct 2, 2026

Where Vor Biopharma Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VOR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:VORBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$697.4M USD
P/E
0.9×
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.25

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Vor Biopharma Inc. · NASDAQ:VORUS$1.18BUS$697.4M0.9×n/an/an/an/an/a1.25
Generate Biomedicines, Inc. · NASDAQ:GENBUS$1.22BUS$895.6Mn/a28.1×n/a3.2×−637.0%0.2×1.90
Taysha Gene Therapies, Inc. · NASDAQ:TSHAUS$1.21BUS$837.4Mn/a153×n/a3.4×n/a0.1×1.69
Mineralys Therapeutics, Inc. · NASDAQ:MLYSUS$1.21BUS$585.1Mn/an/an/a2.4×n/a0.0×1.39
GH Research PLC · NASDAQ:GHRSUS$1.20BUS$841.0Mn/an/an/a3.4×n/a0.0×1.28
Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204US$1.17BUS$1.01Bn/a36.1×n/a3.9×−53.3%0.0×n/a
OPKO Health, Inc. · NASDAQ:OPKUS$1.17BUS$1.26Bn/a2.5×n/a1.0×−29.5%0.4×0.90
D&D Pharmatech Co., Ltd. · KRX:347850US$1.16BUS$1.13Bn/a549×n/a11.5×−785.5%0.8×n/a
CStone Pharmaceuticals · HKEX:2616US$1.16BUS$974.9Mn/a24.1×n/a6.0×−162.1%0.3×n/a
Structure Therapeutics, Inc. · NASDAQ:GPCRUS$1.15B−US$82.92Mn/an/an/a0.9×n/a0.0×1.38
COMPASS Pathways Plc · NASDAQ:CMPSUS$1.14BUS$747.8Mn/an/an/a8.0×n/a0.4×1.65
Median of the othersUS$1.17BUS$868.3M32.1×3.4×−162.1%0.2×1.39

Forecasts

8 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
39.00 USD · Analysts' mean
EPS, year to Dec 2026
-6.67 · 4 analysts

Team and board

Officers

OfficerRole
Jean-Paul KressChief Executive Officer and Chairman
Sandy MahatmeChief Financial Officer, Chief Business Officer
Adi OsovskyGeneral Counsel
Carol LincolnHead of Human Resources
Dallan MurrayChief Commercial Officer
Jeremy SokoloveChief Medical Officer
Navid Z. KhanChief Medical Affairs Officer

Board

DirectorRole
Jean-Paul KressChief Executive Officer and Chairman
Alexander CumboChair of the Compensation Committee
Daniella BeckmanChair of the Audit Committee
David ZaccardelliDirector
Erez KalirMember of the Audit Committee
Fouad NamouniChair of the Nominating and Corporate Governance Committee
Michel DetheuxMember of the Audit Committee

Events

QuarterResultsShare move
Q3 2026Oct 30, 2026 · Before open−5.9%
Q2 2026Aug 11, 2026 · Before open+0.9%
Q1 2026May 13, 2026 · Before open−3.4%
Q4 2025Mar 30, 2026+23.2%
Q3 2025Nov 13, 2025 · After close+2.7%
Q2 2025Aug 12, 2025 · After close+21.7%
Q1 2025May 14, 2025 · After close0.0%
Q4 2024Mar 18, 2025 · Before open−3.8%
Q3 2024Nov 7, 2024 · After close+14.9%
Q2 2024Aug 8, 2024 · After close−1.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−5.5%
Q4 2023Mar 20, 2024 · After close+8.9%
Q3 2023Nov 7, 2023 · After close−6.5%
Q2 2023Aug 10, 2023 · After close+14.4%
Q1 2023May 11, 2023 · After close+0.7%
Q4 2022Mar 23, 2023 · After close+15.3%
Q3 2022Nov 10, 2022 · After close+5.0%
Q2 2022Aug 11, 2022 · After close+8.4%
Q1 2022May 12, 2022 · After close−4.1%
Q4 2021Mar 14, 2022 · After close−0.5%

Open Events

Decks

DeckKindSlidesDate
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting 2026Conference13 slidesOct 2, 2026
Investor Presentation (September 2026)Investor deck60 slidesSeptember 2026
44th Annual J.P. Morgan Healthcare Conference 2026Conference19 slidesJan 12, 2026
Technical Presentation (October 2025)Technical29 slidesOct 28, 2025
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) 2025Conference14 slidesOct 22, 2025
Investor Presentation (September 2025)Investor deck39 slidesSep 2, 2025
Investor Presentation (December 2024)Investor deck38 slidesDec 9, 2024
Investor Presentation (September 2024)Investor deck33 slidesSep 5, 2024
Investor Presentation (January 2024)Investor deck36 slidesJan 5, 2024
Technical Presentation (December 2023)Technical19 slidesDecember 2023
All 13 decks
DeckKindSlidesDate
Technical Presentation (December 2022)Technical35 slidesDec 7, 2022
ESGCT 2021Conference18 slidesOct 21, 2021
ASGCT 2021Conference21 slidesMay 11, 2021

Open Decks

Financings

RaiseDate
At-the-market programme of at-the-market sales
Closed: US$48.4M raised
Aug 11, 2026
Private placement of common stock
Announced: about US$150M · US$10.81 a share
Buyers: RA Capital Management; Forbion (granted the right to appoint one director to the board); Frazier Life Sciences; Caligan Partners; Logos Capital; Venrock Healthcare Capital Partners
Use of proceeds: Clinical development of telitacicept, including Phase 3 trials in myasthenia gravis and primary Sjögren's disease, plus working capital and general corporate purposes
Dec 15, 2025
Public offering of shares
Update: US$115M · US$10 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Citigroup (co-lead), TD Cowen (co-lead)
Nov 13, 2025
Private placement of prefunded warrants
Announced: about US$175M · US$0.25 a share · Warrants at US$0.0001
Buyers: RA Capital Management (existing stockholder); Mingxin Capital; Forbion; Venrock Healthcare Capital Partners; Caligan Partners; NEXTBio
Use of proceeds: To advance development of its clinical pipeline and for general corporate purposes
Jun 25, 2025
Private placement of shares of common stock and accompanying warrants
Announced: about US$55.6M · US$0.9943 a share · Warrants at US$0.838 · Stifel
Dealers: Stifel (lead)
Buyers: Reid Hoffman (led the PIPE as new investor; granted one board seat and one board observer seat); RA Capital Management (existing investor and largest stockholder; participated)
Use of proceeds: Fund clinical and preclinical development of its pipeline candidates and general corporate purposes
Dec 27, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Feb 5, 2021.

Price
US$18.00 a share
Shares offered
9,828,017 shares of common stock
Offering size
US$176.9 million
Underwriters' option
Up to 1,474,202 more shares
Underwriters
Goldman Sachs & Co. LLC, Evercore ISI, Barclays, Stifel · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceNov 6, 2020
Filed publiclyJan 15, 2021
Amended twiceNewest Feb 3, 2021
Shares registered with an exchangeFeb 1, 2021
Declared effective by the SECFeb 4, 2021
Final prospectus, with the priceFeb 8, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Research and development321.5M93.3M94.3M64.5M47.5M31.6M
Operating income-371.6M-121.2M-126.0M-93.4M-69.0M-43.4M
Depreciation and amortization2.89M3.53M3.49M2.52M1.43M605.0K
EBITDA-368.8M-117.7M-122.5M-90.9M-67.6M-42.8M
Net income-696.0M-116.9M-117.9M-92.1M-68.9M-43.3M
Earnings per share, basic-70.50-34.03-1.75-2.33-2.10-230.57
Earnings per share, diluted-70.50-34.03-1.75-2.33-2.10-230.57

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents396.5M81.9M31.4M57.7M119.8M48.5M
Short-term investments58.7M9.98M105.8M172.5M87.7M0
Current assets458.1M96.5M140.8M236.9M214.4M49.1M
Property, plant and equipment533.0K6.58M10.1M12.6M6.85M4.73M
Total assets464.1M142.9M198.1M299.4M242.6M75.9M
Accounts payable5.13M1.50M815.0K1.77M1.54M2.36M
Current liabilities25.2M18.6M15.6M13.1M10.2M10.2M
Total liabilities628.4M46.2M47.4M48.8M26.3M27.6M
Shareholders' equity-164.3M96.7M150.7M250.6M216.3M-59.1M
Shares outstanding38.7M6.24M67.9M66.0M37.2M505.1K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-142.7M-99.7M-100.3M-85.1M-69.1M-36.3M
Capital spending-941.0K-229.0K-1.07M-8.46M-3.89M-4.16M
Free cash flow-143.7M-99.9M-101.4M-93.6M-73.0M-40.5M
Cash from investing-48.8M96.9M71.0M-94.1M-91.7M-4.16M
Cash from financing503.8M53.4M2.94M117.1M232.9M82.5M
Dividends paid000000
Change in cash312.3M50.6M-26.3M-62.1M72.1M42.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
424B5 · ProspectusOct 30, 2026Offer documentSEC
10-Q · Quarterly reportOct 30, 2026Quarterly reportSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
S-3ASR · Registration statementSep 4, 2026Offer documentSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 21, 2026Big-stake noticeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
8-K · Current reportJul 7, 2026Management or board changeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
8-K · Current reportJun 8, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMay 7, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
CORRESP · Letter to the SECMay 4, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 1, 2026Other filingsSEC
S-3 · Registration statementApr 27, 2026Offer documentSEC
ARS · Annual report to shareholdersApr 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 21, 2026Big-stake noticeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 15, 2026Big-stake noticeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 10, 2026Big-stake noticeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 9, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 8, 2026Big-stake noticeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 1, 2026Big-stake noticeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 1, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 30, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 27, 2026Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
424B3 · ProspectusFeb 5, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveFeb 5, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 2, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 30, 2026Other filingsSEC
S-3 · Registration statementJan 29, 2026Offer documentSEC
8-K · Current reportJan 12, 2026ResultsSEC
8-K · Current reportJan 2, 2026Management or board changeSEC
SCHEDULE 13D · Big-stake noticeDec 23, 2025Big-stake noticeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 19, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 19, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 19, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 18, 2025Big-stake noticeSEC
8-K · Current reportDec 18, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeDec 17, 2025Big-stake noticeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
8-K · Current reportDec 9, 2025Management or board changeSEC
424B3 · ProspectusDec 1, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeNov 18, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025Current reportSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
424B5 · ProspectusNov 10, 2025Offer documentSEC
S-3/A · Registration statement, amendedNov 10, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeNov 7, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2025Big-stake noticeSEC
8-K · Current reportNov 3, 2025Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
8-K · Current reportOct 28, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 27, 2025Big-stake noticeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 20, 2025Big-stake noticeSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
144 · Notice of proposed saleOct 20, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 16, 2025Big-stake noticeSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 10, 2025Big-stake noticeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 8, 2025Big-stake noticeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 6, 2025Big-stake noticeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
UPLOAD · Letter from the SECSep 30, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeSep 26, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 25, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansSep 24, 2025Offer documentSEC
S-3 · Registration statementSep 24, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeSep 23, 2025Big-stake noticeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 19, 2025Big-stake noticeSEC
4 · Change in ownershipSep 18, 2025Insider tradeSEC
8-K · Current reportSep 17, 2025Current reportSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 12, 2025Big-stake noticeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 9, 2025Big-stake noticeSEC
3 · Initial statement of ownershipSep 8, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
144 · Notice of proposed saleSep 3, 2025Other filingsSEC
8-K · Current reportSep 2, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 29, 2025Big-stake noticeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
8-K · Current reportAug 27, 2025Management or board changeSEC
8-K · Current reportAug 27, 2025Management or board changeSEC
424B5 · ProspectusAug 27, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
144 · Notice of proposed saleAug 11, 2025Other filingsSEC
DEF 14A · Proxy statementAug 8, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
144 · Notice of proposed saleAug 4, 2025Other filingsSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementJul 29, 2025Meeting noticeSEC
8-K · Current reportJul 22, 2025Management or board changeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 18, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 18, 2025Insider tradeSEC
144 · Notice of proposed saleJul 16, 2025Other filingsSEC
144 · Notice of proposed saleJul 15, 2025Other filingsSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 10, 2025Insider tradeSEC
8-K · Current reportJul 10, 2025Management or board changeSEC
144 · Notice of proposed saleJul 10, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 9, 2025Big-stake noticeSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJun 30, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 27, 2025Big-stake noticeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 27, 2025Insider tradeSEC
8-K · Current reportJun 25, 2025Material contractSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Meeting outcomeSEC
8-K · Current reportMay 20, 2025Management or board changeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
8-K · Current reportMay 8, 2025Management or board changeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 7, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
DEFR14AApr 30, 2025Meeting noticeSEC
8-K · Current reportApr 25, 2025Current reportSEC
ARS · Annual report to shareholdersApr 8, 2025Annual reportSEC

This page holds 200 of 466 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Vor Biopharma Inc.’s releases · as of Oct 26, 2026

Common shares
61,434,344
Fully diluted
61,434,344

Fully diluted

LineSharesAs of
Common shares61,434,344Oct 26, 2026

Share count over time

CountShares
Oct 26, 202661,434,344

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity6.76M11.0%US$129MSep 30, 2026
TCG Crossover Management, LLC5.67M9.2%US$108MSep 30, 2026
Ra Capital Management, L.P.4.5M7.3%US$85.9MSep 30, 2026
Fcpm III Services B.V.3.41M5.5%US$65MSep 30, 2026
BlackRock3.31M5.4%US$63.1MSep 30, 2026
Venrock Adviser, LLC3.04M5.0%US$58MSep 30, 2026
Frazier Life Sciences Management, L.P.2.74M4.5%US$52.4MSep 30, 2026
Vanguard2.68M4.4%US$51.2MSep 30, 2026
State Street1.97M3.2%US$37.6MSep 30, 2026
Caligan Partners LP1.93M3.1%US$36.7MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Great Point Partners LLC1.13M1.8%US$21.5MSep 30, 2026
Millennium992K1.6%US$18.9MSep 30, 2026
Geode Capital980K1.6%US$18.7MSep 30, 2026
Nantahala Capital Management, LLC932K1.5%US$17.8MSep 30, 2026
Paradigm Biocapital Advisors LP890K1.4%US$17MSep 30, 2026
Federated Hermes, Inc.760K1.2%US$14.5MSep 30, 2026
Goldman Sachs746K1.2%US$14.2MSep 30, 2026
Nan Fung Trinity (Hk) LTD722K1.2%US$13.8MSep 30, 2026
Boothbay Fund Management, LLC647K1.1%US$12.3MSep 30, 2026
NEXTBio Capital Management LP621K1.0%US$11.8MSep 30, 2026
Rosalind Advisors, Inc.609K0.99%US$11.6MSep 30, 2026
UBS602K0.98%US$11.5MSep 30, 2026
Marshall Wace, LLP561K0.91%US$10.7MSep 30, 2026
Vivo Capital, LLC550K0.90%US$10.5MSep 30, 2026
Ameriprise537K0.87%US$10.2MSep 30, 2026
ADAR1 Capital Management, LLC531K0.86%US$10.1MSep 30, 2026
Citadel498K0.81%US$9.5MSep 30, 2026
Adage Capital Partners Gp, L.L.C.490K0.80%US$9.35MSep 30, 2026
Franklin Templeton426K0.69%US$8.57MSep 30, 2026
Sphera Funds Management LTD.383K0.62%US$7.32MSep 30, 2026
Susquehanna353K0.57%US$6.74MSep 30, 2026
Integral Health Asset Management, LLC350K0.57%US$6.68MSep 30, 2026
Point72 Asset Management, L.P.343K0.56%US$6.55MSep 30, 2026
Schwab340K0.55%US$6.5MSep 30, 2026
Braidwell LP319K0.52%US$6.09MSep 30, 2026
Northern Trust309K0.50%US$5.89MSep 30, 2026
Eversept Partners, LP268K0.44%US$5.12MSep 30, 2026
Ikarian Capital, LLC250K0.41%US$4.77MSep 30, 2026
D. E. Shaw & Co., Inc.243K0.40%US$4.64MSep 30, 2026
Stempoint Capital LP201K0.33%US$3.83MSep 30, 2026
Woodline Partners LP194K0.32%US$3.71MSep 30, 2026
AQR Capital Management LLC176K0.29%US$3.35MSep 30, 2026
Wellington137K0.22%US$2.61MSep 30, 2026
ExodusPoint Capital Management, LP132K0.21%US$2.51MSep 30, 2026
Axiom Investors LLC124K0.20%US$2.37MSep 30, 2026
Bank of America118K0.19%US$2.24MSep 30, 2026
J. Goldman & Co LP109K0.18%US$2.08MSep 30, 2026
Morgan Stanley101K0.16%US$1.93MSep 30, 2026
BNY97,5570.16%US$1.86MSep 30, 2026
Nuveen90,8450.15%US$1.73MSep 30, 2026

This page holds 50 of 149 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF1.76M2.9%US$32.3MJun 30, 2026
Vanguard Total Stock Market Index Fund1.55M2.5%US$28.6MJun 30, 2026
Fidelity Small Cap Growth Fund1.27M2.1%US$26.9MJul 31, 2026
Select Biotechnology Portfolio1.19M1.9%US$17.8MMay 31, 2026
iShares Russell 2000 ETF952K1.5%US$17.5MJun 30, 2026
Fidelity Small Cap Growth K6 Fund651K1.1%US$13.8MJul 31, 2026
Fidelity Stock Selector Small Cap Fund590K0.96%US$12.5MJul 31, 2026
Vanguard Extended Market Index Fund492K0.80%US$9.06MJun 30, 2026
Fidelity Small Cap Index Fund446K0.73%US$9.44MJul 31, 2026
Fidelity Series Small Cap Opportunities Fund402K0.65%US$8.51MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Small Cap Discovery Fund348K0.57%US$7.36MJul 31, 2026
Fidelity Advisor Biotechnology Fund344K0.56%US$7.27MJul 31, 2026
Fidelity Series Small Cap Discovery Fund298K0.49%US$6.3MJul 31, 2026
iShares Russell 2000 Growth ETF238K0.39%US$4.39MJun 30, 2026
Fidelity Extended Market Index Fund155K0.25%US$2.32MMay 31, 2026
Franklin Biotechnology Discovery Fund149K0.24%US$3.15MJul 31, 2026
iShares Micro-Cap ETF124K0.20%US$2.28MJun 30, 2026
Fidelity Fundamental Small-Mid Cap ETF115K0.19%US$2.44MJul 31, 2026
BlackRock Health Sciences Opportunities Portfolio115K0.19%US$1.72MMay 29, 2026
iShares Russell 2000 Value ETF106K0.17%US$1.96MJun 30, 2026
Schwab Small-Cap Index Fund99,1800.16%US$2.1MJul 31, 2026
Fidelity Small Cap Stock Fund93,2000.15%US$1.97MJul 31, 2026
Master Small Cap Index Series68,8270.11%US$1.27MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF67,0440.11%US$1.23MJun 30, 2026
Small Cap Dynamic Growth Fund65,3450.11%US$978KMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares59,6750.10%US$1.26MJul 31, 2026
Fidelity Total Market Index Fund55,9180.09%US$837KMay 31, 2026
Nuveen Small Cap Blend Index Fund54,0610.09%US$1.14MJul 31, 2026
Fidelity Series Total Market Index Fund45,5020.07%US$681KMay 31, 2026
EQ/2000 Managed Volatility Portfolio40,0830.07%US$738KJun 30, 2026
Federated Hermes MDT Small Cap Core Fund34,5460.06%US$731KJul 31, 2026
Nuveen Equity Index Fund31,0520.05%US$657KJul 31, 2026
LVIP State Street Small-Cap Index Fund29,3000.05%US$539KJun 30, 2026
Fidelity Small Cap Growth Index Fund26,3280.04%US$485KJun 30, 2026
Fidelity Nasdaq Composite Index Fund25,2510.04%US$378KMay 31, 2026
EQ/Small Company Index Portfolio23,8100.04%US$438KJun 30, 2026
Schwab Total Stock Market Index Fund22,2040.04%US$470KJul 31, 2026
Virtus Biotech Clinical Trials Etf21,6440.04%US$458KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund20,9250.03%US$385KJun 30, 2026
Small Cap Index Fund20,5880.03%US$379KJun 30, 2026
Vanguard Balanced Index Fund20,5110.03%US$378KJun 30, 2026
Global X Russell 2000 ETF19,5350.03%US$413KJul 31, 2026
Fidelity Small Cap Value Index Fund17,8220.03%US$328KJun 30, 2026
Biotechnology Ultrasector Profund16,7450.03%US$354KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF15,3570.02%US$325KJul 31, 2026
Siit Small/Mid Cap Fund14,0630.02%US$211KMay 31, 2026
MetLife Russell 2000 Index Portfolio13,8560.02%US$255KJun 30, 2026
Fidelity Nasdaq Composite Index ETF13,7770.02%US$206KMay 31, 2026
State Street Small/Mid Cap Equity Index Portfolio13,6000.02%US$250KJun 30, 2026
SIMT Small Cap Growth Fund13,2160.02%US$243KJun 30, 2026

This page holds 50 of 109 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Shah Rajeev M.
10% owner
Sale213USD 19.75US$4,207Jul 16, 2026
Shah Rajeev M.
Director, 10% owner
Sale165,150USD 15.77US$2.6MApr 22, 2026
Ra Capital Management, L.P.
Director, 10% owner
Sale171,963USD 15.77US$2.71MApr 20, 2026
Ra Capital Management, L.P.
Director, 10% owner
Sale458,411USD 16.28US$7.46MApr 17, 2026
Ra Capital Management, L.P.
Director, 10% owner
Sale53,644USD 16.01US$859KApr 15, 2026
Ra Capital Management, L.P.
Director, 10% owner
Sale153,735USD 15.97US$2.46MApr 14, 2026
Ra Capital Management, L.P.
Director, 10% owner
Sale530,610USD 16.15US$8.57MApr 13, 2026
Shah Rajeev M.
Director, 10% owner
Sale828USD 15.75US$13,041Apr 10, 2026
Shah Rajeev M.
Director, 10% owner
Sale135,201USD 16.59US$2.24MApr 9, 2026
Shah Rajeev M.
Director, 10% owner
Sale353,242USD 16.32US$5.76MApr 8, 2026
All 16 trades
TradeTradeSharesPriceValueDate
Shah Rajeev M.
Director, 10% owner
Sale130,862USD 16.91US$2.21MApr 8, 2026
Kolchinsky Peter
Director, 10% owner
Sale537,754USD 16.51US$8.88MApr 6, 2026
Kolchinsky Peter
Director, 10% owner
Sale44,728USD 17.31US$774KApr 6, 2026
Kolchinsky Peter
Director, 10% owner
Sale6,775USD 18.50US$125KApr 6, 2026
Kolchinsky Peter
Director, 10% owner
Sale258,475USD 18.23US$4.71MApr 2, 2026
Kolchinsky Peter
Director, 10% owner
Sale1,525USD 19.06US$29,066Apr 2, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.19.90%12.9MJul 16, 2026Schedule 13D
Reprogrammed Interchange LLC17.60%1.2MOct 15, 2025Schedule 13D
FMR LLC10.70%6.32MSep 30, 2026Schedule 13G
ForGrowth III PA B.V.9.99%10.2MDec 18, 2025Schedule 13D
Venrock Healthcare Capital Partners III, L.P.9.90%6.44MSep 30, 2026Schedule 13G
Chen Yu9.20%5.67MSep 30, 2026Schedule 13G
Verve Capital Limited6.30%3.41MJun 30, 2026Schedule 13G
BlackRock, Inc.5.70%3.1MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Feb 4, 2021
Alexander Cumbo
Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Climb Bio, Inc. (Director · Since at least Mar 28, 2025); Solid Biosciences Inc. (President and CEO, Director · Since at least Dec 2, 2022); Verve Therapeutics Inc (Director · Since at least Jun 9, 2022); Ra Pharmaceuticals Inc (Director · Nov 14, 2018 – Apr 2, 2020 · Past); Sarepta Therapeutics, Inc. (EVP, Chief Commercial Officer · Mar 5, 2018 – Feb 28, 2020 · Past)
Chair of the Compensation Committee · Since at least Jul 16, 2025
Daniella Beckman
Other companies: Upstream Bio, Inc. (Member, Board of Directors · Since at least Oct 10, 2024); Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 10, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past)
Chair of the Audit Committee · Since at least Feb 4, 2021
Joshua Resnick
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); PepGen Inc. (Director · Since at least Jun 20, 2024); Jade Biosciences, Inc. (Director · Jun 5, 2024 – Jun 5, 2024 · Past)
Director · May 23, 2024 – May 22, 2025 · Past
Matthew R Patterson
Other companies: 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 14, 2023 · Past); Audentes Therapeutics Inc (Chief Executive Officer, Director · Jul 19, 2016 – Jan 15, 2020 · Past)
Director · Feb 4, 2021 – May 22, 2025 · Past
David Zaccardelli
Other companies: SAB Biotherapeutics, Inc. (Chair of the Board · Since at least Jan 5, 2026); Verona Pharma plc (President and CEO, Director · Since at least Aug 7, 2024)
Director · Since at least Jul 7, 2026
Jean-Paul Kress
Other companies: Biogen Inc. (EVP Pres Int'l & Global Hd GTO · Jun 14, 2017 – Jul 3, 2017 · Past); Sarepta Therapeutics, Inc. (Director · Mar 10, 2017 – Mar 10, 2017 · Past)
Chief Executive Officer and Chairman · Since at least Jun 25, 2025
Peter Kolchinsky
Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Jun 12, 2026); ARS Pharmaceuticals, Inc. (Director · Since at least Sep 30, 2025)
Director · Since at least Apr 2, 2026
Wouter Joustra
Other companies: enGene Therapeutics Inc. (Director · Since at least May 15, 2024); NewAmsterdam Pharma Company N.V. (Director · Jul 16, 2024 – Jul 16, 2024 · Past)
Director · Since at least Dec 18, 2025
Amy Quinlan
Other companies: Voyager Therapeutics, Inc. (Principal Accounting Officer · Since at least May 8, 2026)
Vice President of Finance · Jun 21, 2024 – Nov 6, 2024 · Past
All 29 people
PersonSeat
Andrew David Levin
Other companies: Climb Bio, Inc. (Director · Since at least Aug 9, 2021)
Director · Since at least Dec 18, 2025
Dallan Murray
Other companies: Sarepta Therapeutics, Inc. (Chief Customer Officer · Apr 24, 2024 – Mar 7, 2025 · Past)
Chief Commercial Officer · Since at least Aug 4, 2025
Eyal C Attar
Other companies: Aprea Therapeutics, Inc. (SVP, Chief Medical Officer, Director · Oct 2, 2019 – Jun 3, 2022 · Past)
CHIEF MEDICAL OFFICER · Oct 11, 2022 – Feb 13, 2025 · Past
Michel Detheux
Other companies: Iteos Therapeutics Inc (Chief Executive Officer, Director · Since at least Jul 23, 2020)
Member of the Audit Committee · Since at least Jul 16, 2025
Nathan D Jorgensen
Other companies: Voyager Therapeutics, Inc. (Chief Financial Officer · Since at least Jul 8, 2024)
CHIEF FINANCIAL OFFICER · Feb 4, 2021 – May 6, 2024 · Past
Adi OsovskyGeneral Counsel · Since at least Sep 2, 2025
Carol LincolnHead of Human Resources · Since at least Nov 5, 2026
Christopher SlapakChief Medical Officer · Feb 4, 2021 – Feb 1, 2022 · Past
Erez KalirMember of the Audit Committee · Since at least Jan 8, 2025
Fouad NamouniChair of the Nominating and Corporate Governance Committee · Since at least Nov 5, 2026
Han Wook ChoiChief Financial Officer · Sep 30, 2024 – May 1, 2025 · Past
Jeremy SokoloveChief Medical Officer · Since at least Nov 3, 2025
Navid Z. KhanChief Medical Affairs Officer · Since at least Sep 23, 2025
Qing ZurawChief Development Officer · Since at least Jul 17, 2025
Robert AngPRESIDENT AND CEO, Director · Nov 6, 2023 – May 6, 2025 · Past
Sadik KassimChief Technology Officer · Feb 4, 2021 – Feb 4, 2021 · Past
Sandy MahatmeChief Financial Officer, Chief Business Officer · Since at least Jul 10, 2025
Sarah Burgess ReedDirector · Since at least Aug 27, 2025
Tirtha ChakrabortyChief Sci Off & Head Tech Ops · Feb 4, 2021 – May 6, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Vor Biopharma Inc.